Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

ATN-161 in Advanced Renal Cell Cancer

Study:

A Dose-Ranging, Phase II, Open Label Study of ATN 161 in Advanced Renal Cell Cancer

Rationale:

n/a

Purpose:

The purpose of this study is to determine an active dose of ATN-161 for future studies while establishing preliminary evidence of effectiveness in patients with renal cell cancer.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Carcinoma, Renal Cell Drug: ATN-161 Phase 2

Verified by Attenuon December, 2007

Sponsored by: Attenuon
Information provided by: Attenuon
ClinicalTrials.gov identifier: NCT00131651

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Dose Comparison, Parallel Assignment, Pharmacodynamics Study

The Cleveland Clinic Foundation
Cleveland, Ohio 44165
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.